

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

UPDATE ON SUSPENSION OF TRADING AND QUARTERLY UPDATE

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.10(2) and 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Reference is made to the announcements of the Company dated 26 May 2019, 28 May 2019, 4 June 2019, 9 September 2019, 16 September 2019, 24 January 2020, 12 February 2020, 7 April 2020, 23 April 2020, 24 July 2020, 23 October 2020, 8 January 2021, 22 January 2021 and 22 April 2021 respectively (the “**Announcements**”) in relation to, among others, the suspension of trading in the shares of the Company on the Stock Exchange. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements. The board of directors of the Company (the “**Board**”) wishes to provide the shareholders of the Company (the “**Shareholders**”) further update as follows:

RESUMPTION CONDITIONS

As disclosed in the announcement of the Company dated 8 January 2021, the Stock Exchange requested the Company to (i) demonstrate its compliance with Rule 13.24 of the Listing Rules; (ii) publish all outstanding financial results and address any audit modifications; and (iii) re-comply with Rules 3.10, 3.10A, 3.21 and 3.25 of the Listing Rules (the “**Resumption Conditions**”).

Under Rule 6.01A of the Listing Rules, the Stock Exchange may cancel the Company’s listing if trading in the Company’s shares has been suspended for 18 continuous months, expiring on 23 July 2021 (the “**Period**”). The Stock Exchange requests the Company to fulfill the Resumption Conditions before the expiry of the Period to avoid delisting.

LATEST DEVELOPMENT

The Board wishes to inform the Shareholders that a Board meeting is scheduled to be held on Friday, 16 July 2021 for the purpose of, among other matters, considering and approving the unaudited financial results of the Group for the six months ended 30 June 2020 and the audited financial results of the Group for the financial years ended 31 December 2019 and 31 December 2020. It is expected that all outstanding financial results (i.e. the unaudited financial results of the Group for the six months ended 30 June 2020 and the audited financial results of the Group for the financial years ended 31 December 2019 and 31 December 2020) will be published after the same are approved at the Board meeting to be held on Friday, 16 July 2021.

The Company is also in the course of finalising the annual reports for the years ended 31 December 2019 and 31 December 2020 and the interim report for the six months ended 30 June 2020. It is expected that the said annual reports and interim report will be despatched to the Shareholders as soon as possible after the publication of the results announcements for the financial years ended 31 December 2019 and 31 December 2020 and the interim result for the six months ended 30 June 2020.

As disclosed in the announcement of the Company dated 25 June 2021, the Company has appointed Mr. Zhang Ruigen as an independent non-executive Director, member of each of the audit committee, the remuneration committee and the nomination committee of the Board with effect from 25 June 2021. After the appointment, the Company has re-complied with Rules 3.10, 3.10A, 3.21 and 3.25 of the Listing Rules.

On 9 July 2021, the Company has submitted a resumption proposal to the Stock Exchange. The resumption proposal submitted to the Stock Exchange set forth the business, financial and other material information of the Company, including a profit and cashflow forecast to demonstrate that the Company has fulfilled all the Resumption Conditions. In the resumption proposal, the Company has also requested the Stock Exchange to allow the resumption of trading in the shares of the Company. Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules.

Continued suspension of trading

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 24 January 2020 and will remain suspended until the Company fulfills the Resumption Conditions.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sanai Health Industry Group Company Limited
Chen Chengqing
Chairman

Hong Kong, 12 July 2021

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.